While popular drugs like Ozempic and Wegovy are only available as injections, drugmaker Novo Nordisk is working on a more ...

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

Danish drugmaker Novo Nordisk reported fourth quarter and full year 2024 earnings Wednesday, beating Wall Street's ...

Wegovy: sales of weight loss injection more than double - The company said more than 45 million people were now ‘benefitting ...

Novo Nordisk NVO is scheduled to report fourth-quarter 2024 results on Feb. 5, 2025, before the opening bell. The Zacks ...

Metsera is aiming to put its weight loss drug MET-097i, which boasts of a longer half-life, through Phase III trials.

The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...

Novo Nordisk's stock (NVO) rose more than 8% in Friday trading on news that the company's latest weight-loss product ...

Getting skinny on weight loss meds takes a fat wad of cash ... semaglutide is the active ingredient in anti-obesity jabs like Wegovy, and in the anti-diabetes drug Ozempic. Both prescriptions ...

When Rice reached her goal weight, she tried phasing out semaglutide (marketed as Wegovy for weight loss and Ozempic for diabetes), using smaller and less frequent doses to trim costs. She gained ...

Viking's weight loss candidate won't reach commercialization as soon as this year -- but something else this year could boost the stock price -- promising clinical-trial data. Viking shares have ...

Novo Nordisk has struck back in its growing rivalry with Eli Lilly in the obesity market, with data showing a higher-dose version of its oral version of weight loss drug Wegovy hit the mark in a ...